Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Lucie Ellis
UCB's pipeline will see advances across multiple therapy areas in 2018, including more emphasis on new epilepsy indications and unmet needs in neurodegenerative diseases like Alzheimer's.
As the market for pharma and biotech deal making heats up in 2018, Scrip looks at the process of valuing novel companies with emerging data and collects best advice from experts on how start-ups should pitch to potential pharma partners.
In an exclusive interview, Sanofi's head of oncology development Joanne Lager explains how the French big pharma could make a comeback in cancer this year and highlights its immunotherapy combination opportunities.
Santhera has moved into cystic fibrosis via a global licensing deal with Polyphor, expanding its rare disease pipeline.
Merck's verubecestat has flopped in a second Phase III Alzheimer's trial; investors are anticipating M&A or licensing deals soon to bring something new into the big pharma's development portfolio.
Johnson & Johnson Innovation has opened its first JLABS incubator in Europe, the 10th worldwide, with close links to its pharma R&D unit Janssen.